Peptide Reports

BPC-157

Community Protocol

BPC-157

Preparation examples, syringe conversion, community-reported patterns and human-evidence limitations.

Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.

Scope

Preparation examples, syringe conversion, community-reported patterns and human-evidence limitations.

Available strengths: 5 MG and 10 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

SetupDiluentConcentrationUnit conversion
5 MG vial – 2.0 mL exampleAdd 2.0 mL bacteriostatic water2.5 mg/mLEach U-100 unit = 25 mcg
10 MG vial – 2.0 mL exampleAdd 2.0 mL bacteriostatic water5 mg/mLEach U-100 unit = 50 mcg

Syringe Conversion

Reported amount5 MG setup10 MG setup
100 mcg4 units2 units
250 mcg10 units5 units
500 mcg20 units10 units
750 mcg30 units15 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring reportFrequency seenContext in reports
250 mcgOnce dailyLower-start and tolerance reports
250 mcgTwice dailyFrequently repeated split pattern
500 mcgOnce dailyFrequently repeated daily total

Observations

  • The reviewed discussions most often clustered around 250-500 mcg total per day.
  • Both once-daily and split morning/evening administration were reported; no validated human schedule exists.
  • Users discussed tendon, muscle, joint and digestive goals, but these anecdotes cannot establish efficacy.

Caveats

  • Published human exposure is too limited to characterize BPC-157 safety, pharmacokinetics or an appropriate subcutaneous dose.
  • Product identity, purity, sterility and concentration cannot be inferred from online reports, and animal findings do not establish human benefit.

Sources

  1. FDA briefing document: BPC-157 human-safety evidence
  2. PubMed: Regeneration or Risk? A Narrative Review
  3. r/Peptides, subcutaneous dosage discussion
  4. r/Peptides, BPC-157 dosage discussion
  5. r/Peptides, BPC-157 and TB-500 dosing discussion